In its latest Phase 2 trial at three major Israeli hospitals, MesenCure from Israel’s Bonus BioGroup (see here previously) reduced Covid-19 deaths to 6.7% compared to 23.3% of the control group. It is now aiming for emergency use authorization in US, EU, and Israel.

https://www.jpost.com/health-and-wellness/coronavirus/israeli-drug-for-severe-covid-reduces-death-by-70-percent-phase-2-trial-686879